SE9904483D0 - New use - Google Patents

New use

Info

Publication number
SE9904483D0
SE9904483D0 SE9904483A SE9904483A SE9904483D0 SE 9904483 D0 SE9904483 D0 SE 9904483D0 SE 9904483 A SE9904483 A SE 9904483A SE 9904483 A SE9904483 A SE 9904483A SE 9904483 D0 SE9904483 D0 SE 9904483D0
Authority
SE
Sweden
Prior art keywords
patient
prodrug
administering
molecular weight
effective amount
Prior art date
Application number
SE9904483A
Other languages
Swedish (sv)
Inventor
Christer Mattsson
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9904483A priority Critical patent/SE9904483D0/en
Publication of SE9904483D0 publication Critical patent/SE9904483D0/en
Priority to PCT/SE2000/002433 priority patent/WO2001041796A1/en
Priority to AU19124/01A priority patent/AU1912401A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method of combating undesirable cell proliferation in a patient the method comprising administering to the patient an effective amount of a low molecular weight thrombin inhibitor or a prodrug thereof. A method of preventing neointimal hyperplasia in a patient the method comprising administering to the patient an effective amount of a low molecular weight thrombin inhibitor or a prodrug thereof.
SE9904483A 1999-12-08 1999-12-08 New use SE9904483D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE9904483A SE9904483D0 (en) 1999-12-08 1999-12-08 New use
PCT/SE2000/002433 WO2001041796A1 (en) 1999-12-08 2000-12-05 Method of combating undesirable hyperplastic cell proliferation
AU19124/01A AU1912401A (en) 1999-12-08 2000-12-05 Method of combating undesirable hyperplastic cell proliferation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9904483A SE9904483D0 (en) 1999-12-08 1999-12-08 New use

Publications (1)

Publication Number Publication Date
SE9904483D0 true SE9904483D0 (en) 1999-12-08

Family

ID=20418040

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9904483A SE9904483D0 (en) 1999-12-08 1999-12-08 New use

Country Status (3)

Country Link
AU (1) AU1912401A (en)
SE (1) SE9904483D0 (en)
WO (1) WO2001041796A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10064797A1 (en) * 2000-12-22 2002-06-27 Knoll Ag Combination pack useful for the treatment of e.g. deep vein thrombosis and post-operative thrombosis, containing oral and parenteral formulations of thrombin inhibitor prodrugs
KR20050057294A (en) 2002-09-09 2005-06-16 트라이젠 리미티드 Boronic acid salts and their use in the treatment of thrombosis
US20050288253A1 (en) 2002-09-09 2005-12-29 Trigen Limited Boronic acid salts

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2060284T3 (en) * 1990-04-23 1994-11-16 Sanofi Elf A PROCEDURE FOR THE PREPARATION OF A CARBOHYDRATE DERIVATIVE INCLUDING A TRISACARIDE UNIT.

Also Published As

Publication number Publication date
WO2001041796A1 (en) 2001-06-14
AU1912401A (en) 2001-06-18

Similar Documents

Publication Publication Date Title
TR200103493T2 (en) Metalloprotease inhibitors
TR200201505T2 (en) Pirazolopyrimidines as therapeutic agents
CY1110385T1 (en) Use of IL-18 inhibitors for the treatment and / or prevention of atherosclerosis
CR6682A (en) NON-PEPTIDIC INHIBITORS OF THE VLA-4 DEPENDENT CELL UNION IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE AND RESPIRATORY DISEASES
DE60016402D1 (en) THERAPEUTIC USE OF AN INHIBITOR OF THE HEDGEHOG SIGNAL TRANSMISSION PATH
DK1216038T3 (en) Use of inhibitors of the renin angiotensin system in the prevention of cardiovascular events
SE0301886D0 (en) New use V
TR199901417T2 (en) New compositions with analgesic effect.
SE0301882D0 (en) New use I
DK1156806T3 (en) Pharmaceutical composition containing proton pump inhibitor
ATE495187T1 (en) DALDA ANALOGUES AND THEIR USE
SE0101932D0 (en) Pharmaceutical combinations
NZ513096A (en) Compositions for treating inflammatory response
ATE319473T1 (en) MELAGATRAN FOR THE TREATMENT OF INFLAMMATION
SE9902267D0 (en) New compounds
CY1105317T1 (en) USE OF 6-DIMETHYLAMINOMETHYL-1-PHENYL-CYCLOHEXANE SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF URINARY INCONTINENCE
CY1105142T1 (en) USE OF 6-DIMETHYLAMINOMETHYL-1-PHENYL-CYCLOHEXANE SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF URINARY INCONTINENCE
HUP9801022A2 (en) Use of aldose reductase inhibitor in preventing or reversing diabetic cardiomyopathy
IS6130A (en) Anti-inflammatory treatment for inflammation associated with infection
SE9802209D0 (en) Novel compounds
EE200300129A (en) Use of distamycin alpha-haloacryloyl derivative
SE9904483D0 (en) New use
AR043327A1 (en) USE OF QUINURENINE 3- HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES
TR200302134T4 (en) Use of 2-methyl-thiazolidine-2,4-dicarboxylic acid and / or physiologically acceptable salts thereof as anti-cancer agents.
TR200103151T2 (en) A pharmaceutical formulation containing a carboxypeptidase U inhibitor and a thrombin inhibitor.